# Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

> **NCT03107611** · PHASE3 · COMPLETED · sponsor: **Mylan Inc.** · enrollment: 654 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Pimecrolimus Cream, 1%
- **DRUG:** Placebo Cream
- **DRUG:** Pimecrolimus Cream, 1%

## Key facts

- **NCT ID:** NCT03107611
- **Lead sponsor:** Mylan Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-29
- **Primary completion:** 2017-05-15
- **Final completion:** 2017-05-15
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2022-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03107611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03107611, "Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03107611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*